Neuropeptide mixture derived from pig brain tissue. Contains BDNF, NGF, GDNF, CNTF, and other neurotrophic peptide fragments. Studied for Alzheimer's disease, traumatic brain injury, stroke recovery, and ADHD. Widely used in Russia and China.
Multiple peptide components with varying pharmacokinetics; IV/IM administration only
SKUs
1
Evidence
Moderate Evidence
Cerebrolysin is a mixture of peptide fragments derived from pig brain protein that has been studied for neurodegenerative conditions including Alzheimer's disease, stroke recovery, and traumatic brain injury. It is approved and used clinically in several European and Asian countries, though it does not have FDA approval in the United States.
Alzheimer's Disease Research
Several clinical trials have examined cerebrolysin in mild-to-moderate Alzheimer's disease. Some trials showed improvements in cognitive measures and activities of daily living compared to placebo, though the evidence is considered mixed and the quality of trials has been criticized. A Cochrane review found some positive signals but noted methodological limitations.
Stroke Recovery
Cerebrolysin has been studied as an add-on treatment to support neurological recovery after ischemic stroke. Some trials have shown improvements in functional outcomes and motor recovery, particularly when started early after stroke onset. It is used clinically for this purpose in several countries.
Traumatic Brain Injury
Research has examined whether cerebrolysin can support recovery after traumatic brain injury. Animal studies show neuroprotective effects, and some human trials have been conducted. The evidence base is smaller than for stroke and Alzheimer's applications.
Some clinical trials show improvements in cognition and daily function in Alzheimer's disease, though evidence quality is debated.
Trials in stroke recovery suggest possible functional improvements, particularly with early treatment.
Approved for clinical use in multiple European and Asian countries based on the accumulated evidence.
Animal studies consistently show neuroprotective signals across multiple injury and disease models.
No FDA approval; regulatory assessments in Western countries have generally not found evidence strong enough for approval.
The evidence base for cerebrolysin is contentious. Many of the positive trials were conducted in Eastern Europe or Asia, and Western regulatory bodies have generally not found the evidence sufficient to support approval. Cochrane reviews have noted methodological concerns in many trials. The fact that it is a complex mixture of peptide fragments makes standardization and reproducibility challenging. It is not FDA-approved.
Cerebrolysin is not a single compound — it is a standardized mixture of short peptide fragments produced by breaking down proteins from pig brain tissue. These fragments are thought to act similarly to naturally occurring neurotrophic factors — proteins that support the survival, growth, and function of nerve cells. In animal and some human studies, it appears to reduce neuronal death after injury, support the formation of new connections between neurons, and reduce inflammation in brain tissue. The exact which fragments are responsible for which effects, and the precise receptor interactions, are not fully mapped out, which is one reason its mechanism of action is harder to characterize than a single-molecule drug.
Cerebrolysin is generally considered well-tolerated in the populations studied. Common side effects include dizziness, agitation, and GI symptoms. Because it is derived from animal (porcine) tissue, there are theoretical concerns about prion disease transmission, though no cases have been linked to the product and manufacturing processes are designed to address this. It is not FDA-approved and should be considered investigational in the US context.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
5–30mL IV daily for acute conditions in published trials; 5mL IM in maintenance protocols
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Cerebrolysin in Alzheimer's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
Dementia and Geriatric Cognitive Disorders • 2004
• DOI: 10.1159/000081802
Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts
Nanotechnology Approaches for Prevention and Treatment of Chemotherapy-Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors
Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage
Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial
Phytochemical and Fungal Bioactive Compounds in the "Brain Health Triad": A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy
Neural regeneration in the human central nervous system-from understanding the underlying mechanisms to developing treatments. Where do we stand today?
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.